rs1532278 — CLU CLU Alzheimer's risk variant

Intronic regulatory variant in CLU (clusterin/apolipoprotein J) that controls neuronal clusterin expression; the protective T allele elevates CLU transcription, enhancing amyloid-beta clearance across the blood-brain barrier and reducing Alzheimer's disease risk

See your personal result for CLU

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CLU and Alzheimer's Disease — Your Brain's Amyloid Clearance Gene

Clusterin (CLU), also known as apolipoprotein J, is the third strongest known genetic risk factor for late-onset Alzheimer's disease after APOE and BIN1. It is a secreted molecular chaperone that binds misfolded proteins — including amyloid-beta (Aβ) — and escorts them out of the brain across the blood-brain barrier. The rs1532278 variant sits in an intronic regulatory region of the CLU gene and is one of the most studied and most robustly replicated Alzheimer's risk loci in the entire human genome.

The Mechanism

CLU exerts its neuroprotective effect through two overlapping pathways. First, secreted clusterin forms stable complexes with Aβ and facilitates its clearance from the brain across the blood-brain barrier11 blood-brain barrier
the highly selective barrier between brain tissue and circulating blood via the LRP2 receptor. Second, CLU inhibits Aβ oligomerization and aggregation directly, preventing the formation of the toxic soluble oligomers that damage synapses before plaques ever appear.

Rs1532278 is located in an intronic open chromatin region — a regulatory element — in glutamatergic (excitatory) neurons. A 2025 study using CRISPR editing of human iPSC-derived neurons showed that only rs1532278 among all CLU locus variants sits in an accessible chromatin region in neurons22 only rs1532278 among all CLU locus variants sits in an accessible chromatin region in neurons
Zhao et al., Molecular Neurodegeneration, 2025. The T allele creates stronger binding for the ISL2 transcription factor, retaining approximately 80% more binding capacity than the C allele. This drives elevated neuronal CLU transcription and secretion.

The protective T allele's downstream effect is measurable: T/T carriers show approximately 40–50% higher CLU mRNA expression in glutamatergic neurons compared to C/C carriers, along with greater dendritic complexity, enhanced synaptic marker expression, and higher neuronal firing frequency. Elevated neuronal CLU promotes neuron-to-astrocyte lipid transfer, increasing astrocytic lipid droplet accumulation and fine-tuning glutamate clearance — a lipid-mediated neuron-glia communication pathway that supports neuronal resilience.

The Evidence

CLU was first identified as an Alzheimer's risk locus in the landmark 2009 Harold et al. GWAS33 2009 Harold et al. GWAS
Harold et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009 (5,964 cases + controls, OR = 0.86 for the protective haplotype). Rs1532278 is in near-complete linkage disequilibrium with rs11136000 (r² = 0.95, D′ = 0.99), the originally reported CLU lead SNP — but rs1532278 shows slightly stronger association with ventricular expansion and Aβ deposition, suggesting it sits closer to the true causal variant.

A 2010 meta-analysis confirmed the CLU association across 15,000+ individuals44 confirmed the CLU association across 15,000+ individuals
Jun et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci. Archives of Neurology, 2010 (OR = 0.91, 95% CI 0.85–0.96), and showed the CLU effect is independent of APOE ε4 status — unlike PICALM, whose effect is largely confined to ε4 carriers. The 2025 functional study reported an even more significant signal at rs1532278 specifically: OR = 0.905 with p = 3.2 × 10⁻³³ in a large meta-GWAS.

Plasma clusterin levels serve as a biomarker for AD progression. Elevated plasma clusterin in MCI predicted progression to AD with HR = 18.655 Elevated plasma clusterin in MCI predicted progression to AD with HR = 18.6
Jongbloed et al. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. J Alzheimers Dis, 2015 and correlated with faster cognitive decline (r = −0.38). Notably, C/C homozygotes have higher plasma clusterin concentrations, reflecting a compensatory upregulation in response to reduced brain clearance efficiency.

Practical Actions

Rs1532278 C/C and C/T carriers do not have a pathogenic variant — this is a common risk-modifying SNP, not a disease-causing mutation. The C allele is carried by approximately 86% of people in some form (C/C or C/T). Practical focus for C-allele carriers is on lifestyle factors that support the CLU-Aβ clearance pathway: omega-3 fatty acids support neuronal membrane integrity and reduce neuroinflammation at CLU-relevant pathway nodes; aerobic exercise increases CLU expression in hippocampal tissue; and avoiding chronic sleep deprivation is specifically relevant because Aβ clearance via the glymphatic system is maximally active during deep sleep — a pathway that overlaps functionally with CLU-mediated BBB clearance.

Monitoring cognition from midlife is meaningful for C/C homozygotes: baseline cognitive assessments with standardized tools (MoCA or MMSE) in the 40s–50s provide early-change detection before symptoms are clinically apparent.

Interactions

The strongest known interaction is with APOE. APOE ε4 and CLU risk alleles both impair Aβ clearance through related but distinct mechanisms — APOE via direct Aβ binding competition and receptor-mediated clearance at LRP1, CLU via LRP2 — and carriers of both risk alleles show amplified ventricular expansion rates and accelerated Aβ accumulation in imaging studies. This CLU × APOE interaction is documented in the literature and is a strong candidate for a compound action (see interaction candidates below).

The CLU locus also contains rs9331888 (exon 1) and rs7982 (exon 5), which affect alternative splicing of CLU transcripts in a sex-dependent manner. These three variants are in partial LD and tag different functional effects within the same gene — rs1532278 affects transcription in neurons, rs9331888 affects splicing, and rs7982 affects intron retention primarily in females.

Genotype Interpretations

What each possible genotype means for this variant.

CC Population-Risk Genotype Normal

Common CLU genotype — baseline Alzheimer's risk

The C allele at rs1532278 is associated with reduced transcription factor (ISL2) binding at the intronic regulatory element controlling neuronal CLU expression. C/C carriers show approximately 40–50% lower CLU mRNA in glutamatergic neurons compared to T/T carriers. This reduced expression modestly impairs the CLU-LRP2 amyloid-beta clearance pathway at the blood-brain barrier, and is reflected in observational data showing higher plasma clusterin levels in C/C individuals — interpreted as a compensatory upregulation of hepatic and glial CLU in response to the reduced neuronal contribution.

Clinically, the effect size is modest: OR = 0.905 for the T allele means C/C homozygotes have a roughly 10–20% higher relative risk of late-onset AD compared to T/T carriers at this locus. This translates to a small absolute risk increment and is substantially smaller than the effect of APOE ε4 or family history. Lifestyle optimization and early cognitive monitoring are the most practical responses.

TT Enhanced CLU Protection Beneficial

Two protective T alleles — highest CLU expression and strongest Alzheimer's protection at this locus

The T allele is a human-specific derived allele that arose after the human-chimpanzee split. It creates a stronger ISL2 transcription factor binding site at the intronic regulatory element controlling neuronal CLU expression. T/T neurons in isogenic iPSC models show not just higher CLU mRNA but measurable functional differences: greater dendritic branching, higher synaptic marker levels (SYP, PSD-95), and increased action potential firing frequency compared to C/C cells. These functional metrics parallel the gene-expression findings.

CLU is elevated in cerebrospinal fluid and brain tissue in Alzheimer's disease — interpreted as a reactive compensatory response to amyloid load. Carriers of T alleles appear to sustain this protective response more efficiently at baseline, potentially delaying or reducing the threshold for pathological progression. The protective effect at rs1532278 is independent of APOE genotype, meaning T/T protection holds even in APOE ε4 carriers.

CT Partial CLU Protection Intermediate

One protective T allele — partial benefit to CLU expression

The additive model fits rs1532278 well: each T allele reduces Alzheimer's disease risk by approximately 9–10% (OR ~0.905), so C/T heterozygotes sit midway between C/C and T/T in terms of neuronal CLU expression and Aβ-clearance efficiency. CRISPR-edited iPSC neuron studies confirm the dose-response: T/T cells show the highest CLU mRNA, dendritic complexity, and synaptic marker expression; C/T cells show intermediate values; C/C cells show the lowest.

Plasma clusterin monitoring has clinical relevance for C/T carriers — rising plasma CLU concentrations in midlife (before cognitive symptoms) have been associated with accelerated progression in MCI cohorts, providing an early warning signal that the compensatory response is under strain.